Payment overview · 2025
General Payments
$50.23
3 reported records · 2 companies
Healthcare provider profile · identity verified
Clayton Bert Alexander, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LA PORTE, IN · NPI 1992794879
Verified facts
What the public records show
CMS Open Payments records show Clayton Bert Alexander, D.O. received $50.23 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 63.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synjardy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.10 | 63.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.13 | 36.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.23 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.10 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 286 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 60 |
| Omeprazole | Omeprazole | 218 | 48 |
| Glimepiride | Glimepiride | 202 | 42 |
| Lisinopril | Lisinopril | 194 | 50 |
| Gabapentin | Gabapentin | 185 | 41 |
| Alprazolam | Alprazolam | 184 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 31 |
| Metformin Hcl | Metformin Hcl | 151 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 32 |
| Eliquis | Apixaban | 130 | 18 |
| Carvedilol | Carvedilol | 126 | 35 |
| Jardiance | Empagliflozin | 123 | 29 |
| Simvastatin | Simvastatin | 123 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 37 |
| Metformin Hcl Er | Metformin Hcl | 116 | 31 |
| Prednisone | Prednisone | 116 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 28 |
| Ezetimibe | Ezetimibe | 100 | 23 |
| Losartan Potassium | Losartan Potassium | 99 | 28 |
| Celecoxib | Celecoxib | 98 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 25 |
| Furosemide | Furosemide | 95 | 21 |
| Memantine Hcl | Memantine Hcl | 95 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 27 |
| Potassium Chloride | Potassium Chloride | 92 | 27 |
| Montelukast Sodium | Montelukast Sodium | 89 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 26 |
| Meloxicam | Meloxicam | 84 | 21 |
| Ozempic | Semaglutide | 81 | 14 |
| Allopurinol | Allopurinol | 78 | 19 |
| Pregabalin | Pregabalin | 78 | suppressed |
| Lorazepam | Lorazepam | 76 | suppressed |
| Spironolactone | Spironolactone | 74 | 23 |
| Sertraline Hcl | Sertraline Hcl | 72 | 18 |
| Irbesartan | Irbesartan | 65 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 12 |
| Tramadol Hcl | Tramadol Hcl | 62 | 15 |
| Donepezil Hcl | Donepezil Hcl | 60 | suppressed |
| Atenolol | Atenolol | 59 | 15 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Finasteride | Finasteride | 57 | 11 |
| Azithromycin | Azithromycin | 56 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 19 |
| Doxepin Hcl | Doxepin Hcl | 54 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 23 |
| Temazepam | Temazepam | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 19 |
| Carisoprodol | Carisoprodol | 44 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 18 |
| Torsemide | Torsemide | 38 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 17 |
| Diazepam | Diazepam | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 19 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Roflumilast | Roflumilast | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 27 |
| Famotidine | Famotidine | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 15 |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Estradiol | Estradiol | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Fetzima | Levomilnacipran Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Jatenzo | Testosterone Undecanoate | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.23 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, JARDIANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error